Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 18 Apr 2009 Actual patient number (181) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.